Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

Product development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ContextLogic Inc

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases. It is committed to delivering genetic medicine to pediatric patients with rare diseases. Their proprietary technology based on the non-pathogenic adeno-associated viral vector offers superior efficiency and safety compared to all competitors on the market and is uniquely suited for the treatment of children as well as adults.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ContextLogic Inc. focuses on achieving its strategic goals of acquiring and/or building operating businesses. Previously, the company sold substantially all its operating assets and liabilities. ContextLogic was founded by Piotr Szulczewski and Danny Zhang in June 2010 and is headquartered in Oakland, CA.

LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

LogicBio Therapeutics (LOGC) Catches Eye: Stock Jumps 7.1%

NEW YORK, May 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the "Class Period") of the important May 18, 2020 lead...

LOGC FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Reminds LogicBio Investors of Important Deadline in Securities Class Action - LOGC

CAMBRIDGE, Mass., March  16, 2020  (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that Mark Enyedy has been appointed to its Board of Directors, effective as of March 17, 2020. Mr. Enyedy, who brings over 25 years of deep experience in biotech management, strategy, and corporate development, currently serves as President and Chief Executive Officer of Immunogen, Inc. Tomer Kariv, Esq., co-founder and Chief Executive Officer of Pontifax, is stepping down due to time commitments relating to his other business obligations after serving as a member of the Board of Directors since June 2017.

LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors

LogicBio: A Speculative Buy For Their GeneRide Platform Based Gene Therapies

CAMBRIDGE, Mass., Feb.  10, 2020  (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions. The Company submitted the IND in January 2020 to support the initiation of a Phase 1/2 clinical trial in patients with MMA. LogicBio expects that the FDA questions will be provided in writing within 30 days. LogicBio plans to work closely with the FDA to resolve these questions as quickly as possible.  

LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia

– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –  – Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –  – Established research collaboration with Takeda for GeneRide in Crigler-Najjar Syndrome (CN) –

LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones

CAMBRIDGE, Mass., Dec.  17, 2019  (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has entered into an exclusive license with Oregon Health & Science University (“OHSU”) to intellectual property rights owned by OHSU while also extending  a sponsored research agreement (“SRA”) to explore methods for enhancing selective advantage of edited hepatocytes using pharmacological agents with the laboratory of Markus Grompe, M.D., professor at OHSU. The initial phase of the research program provided proof-of-principle of enhanced selective advantage for cells edited by GeneRide™ in pilot murine experiments. This extension phase will focus on translating the enhancement strategy to non-human primates, a critical step before clinical translation to future GeneRide candidates and other technologies. GeneRide™ is LogicBio’s proprietary promoterless, nuclease-free genome editing technology, which is designed to provide a stable therapeutic effect by harnessing homologous recombination to precisely integrate corrective genes into a patient’s genome and leveraging endogenous promoters to drive gene expression. 

LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates 

News for ContextLogic Inc Stock (LOGC)